drugset / Trial / NCT00595972
Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and tolerability of the ECF regimen (epirubicin, cisplatin and FU) combined with endostar-- a inhibitor of angiogenesis, in patients with advanced or metastatic gastric cancer (A/MGC).
Timeline
- Start
- 2007-11
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 7.5 mg/m2 | — |
| Background | Cisplatin | Other / unclassified | 60 mg/m2 | — |
| Background | ECF-endostar | Unknown | 500 mg/m2 | — |
| Background | Epirubicin | Small molecule | 50 mg/m2 | — |